Filter posts

Report: Low Compliance with ACA Charity Care Requirements among 340B Hospitals

Earlier this week, the Alliance for Integrity and Reform of 340B, of which BIO is …

Points to Consider about the Center for American Progress Prescription Drug Discussion

This afternoon, the Center for American Progress (CAP) Action Fund hosted an obviously one-sided discussion …

Facing growing pressure, N.Y. insurers agree to lift restrictions on hepatitis c therapies

Last week, we wrote about the mounting evidence of insurer discrimination and coverage denials for …

ICYMI: One Patient’s Perspective: Having Cancer Doesn’t Make Me Worth Less

Yesterday, cancer survivor and health economist Jennifer Hinkel shared her perspective on the Institute for …

Patient and provider groups ask CMS: Don’t turn back the clock on rheumatic disease care

Writing today in The Hill, Ann Palmer of the Arthritis Foundation and Joan Von Feldt …

Evidence Mounts of Insurer Discrimination against HIV, HCV Patients

We’ve written before about the problem of discriminatory formulary design in health insurance plans, particularly …

New Reports: Insurance Plans Shifting More Costs to Patients

A new report out this week from the Kaiser Family Foundation showed that patient out …

Morning Consult: Medicare’s Flawed Part B Drug Experiment Could Harm Patients

In today’s Morning Consult, the Community Oncology Alliance’s Rose Gerber has an excellent piece detailing …

Will your company be the “Buzz of BIO"?

Anyone who has ever attended the BIO International Convention can attest to the intensity and …

Harvard Analysis of Discriminatory Formulary Design in 2016 Health Plans

BIO supports policy changes that protect patients’ ability to obtain access to the prescription drugs …